That study (Frag-X) was with CX-516. This article is a little misleading. He does make a couple interesting points though, and his mention of Glaxo's AMPA upmodulator being in Phase 1 is news.
His mention of Lilly's compound failure brings up an interesting subject. In a conf call several years ago, Dr. Stoll made an offhand remark that at that time at least, the FDA likely didn't even know the difference between a high impact and a low impact Ampakine. That may still be the case to some extent, with Cortex's low impacts being viewed with heightened suspicion after the failure of the Lilly drug a couple years ago. The two compounds don't even act at the same receptor binding site, but in people's minds are lumped together under the same broad AMPA category. So there is probably some degree of "guilt by association".
Market Data 
Markets 
AI
